London
A breast cancer patient this week sued Britain’s National Health Service for refusing to give her a drug that could save her life. Elaine Barber, a 41-year-old mother of four, was told that prescribing Herceptin, a new drug that costs up to $50,000 a year per patient, was not “a cost-effective use of finite health resources.” Last month, though, a different patient was given the drug on the grounds that her status as a single mother of a disabled child rendered her case “exceptional.” In most E.U. countries, drugs are made available through public health systems as soon as they get an E.U. license. But in Britain, drugs must also undergo a cost-benefit analysis.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Why UK scientists are trying to dim the SunIn The Spotlight The UK has funded controversial geoengineering techniques that could prove helpful in slowing climate change
-
Gandhi arrests: Narendra Modi's 'vendetta' against India's oppositionThe Explainer Another episode threatens to spark uproar in the Indian PM's long-running battle against the country's first family
-
How the woke right gained power in the USUnder the radar The term has grown in prominence since Donald Trump returned to the White House
